Copyright
©The Author(s) 2017.
World J Gastroenterol. Nov 7, 2017; 23(41): 7387-7396
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7387
Published online Nov 7, 2017. doi: 10.3748/wjg.v23.i41.7387
Table 1 Patient characteristics according to clinical course
| Relapse (n = 47) | Remission (n = 102) | P | |
| Age (in yr, mean ± SD, range) | 43.9 ± 17.5 (17-76) | 38.1 ± 14.6 (17-76) | NS |
| Male | 28 (59.6%) | 49 (48.0%) | 0.078 |
| Disease duration (in mo, mean ± SD, range) | 95.1 ± 118.7 (1-560) | 95.3 ± 162.0 (1-1415) | NS |
| Diagnosis | |||
| Crohn’s disease | 38 (80.9%) | 75 (73.5%) | NS |
| Ulcerative Colitis | 9 (19.1%) | 27 (26.5%) | NS |
| Disease location | NS | ||
| Ileal (L1) | 16 | 22 | |
| Colonic (L2) | 4 | 14 | |
| Ileocolonic (L3) | 28 | 29 | |
| Perianal disease (p) | 7 | 11 | |
| Proctitis | 1 | 7 | |
| Left sided | 3 | 8 | |
| Extensive | 5 | 12 | |
| Extraintestinal manifestations | 18 | 35 | NS |
| Fecal calprotectin (in μg/g, median, IQR) | 481 (286-600) | 89 (36-180.8) | < 0.001 |
| CRP (in yr, mean ± SD, range) | 11.3 ± 10.1 (3.0-41.0) | 5.1 ± 5.5 (3.1-42.0) | 0.002 |
| WBC (in thousands, mean ± SD, range) | 8.9 ± 3.3 (3.4-18.2) | 7.5 ± 2.4 (3.8-18.4) | 0.022 |
| Hgb (in g/dL, mean ± SD, range) | 13.2 ± 1.9 (9.7-16.5) | 13.6 ± 1.5 (10.0-16.4) | NS |
| PLT (in thousands, mean ± SD, range) | 277.5 ± 99.5 (117-511) | 256.0 ± 61.4 (103-450) | NS |
- Citation: Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396
- URL: https://www.wjgnet.com/1007-9327/full/v23/i41/7387.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i41.7387